Zobrazeno 1 - 10
of 161
pro vyhledávání: '"Kerry A. Rogers"'
Autor:
Kaitlin Annunzio, Michael Ozga, Ying Huang, Mirela Anghelina, Seema A. Bhat, James S. Blachly, Michael R. Grever, Gerard Lozanski, Jasmine Neal, Polina Shindiapina, Kerry A. Rogers
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 1200-1202 (2023)
Externí odkaz:
https://doaj.org/article/f5a5e4450cd243178370f7aac4d9c690
Autor:
Farhad Ravandi, Robert J. Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly, Alessandro Broccoli, Timothy Call, Dai Chihara, Claire Dearden, Judit Demeter, Sasha Dietrich, Monica Else, Narendranath Epperla, Brunangelo Falini, Francesco Forconi, Douglas E. Gladstone, Alessandro Gozzetti, Sunil Iyengar, James B. Johnston, Jeffrey Jorgensen, Gunnar Juliusson, Francesco Lauria, Gerard Lozanski, Sameer A. Parikh, Jae H. Park, Aaron Polliack, Graeme Quest, Tadeusz Robak, Kerry A. Rogers, Alan Saven, John F. Seymour, Tamar Tadmor, Martin S. Tallman, Constantine S. Tam, Philip A. Thompson, Xavier Troussard, Clive S. Zent, Thorsten Zenz, Pier Luigi Zinzani, Bernhard Wörmann, Kanti Rai, Michael Grever
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 12, Pp 1-7 (2022)
Abstract A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent natur
Externí odkaz:
https://doaj.org/article/b522c851a9074f98bd78424982d9e633
Autor:
Elizabeth M. Muhowski, Janani Ravikrishnan, Britten Gordon, Lianbo Yu, Shrilekha Misra, Brandi Walker, Sudharshan Eathiraj, Deepa Sampath, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-5 (2022)
Abstract Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL). The first-in-class covalent BTK inhibitor, ibrutinib, produces durable r
Externí odkaz:
https://doaj.org/article/cbd3349984cb4091abe926011ab6ccf0
Autor:
Janek S. Walker, Zachary A. Hing, Bonnie Harrington, Jordan Baumhardt, Hatice Gulcin Ozer, Amy Lehman, Brian Giacopelli, Larry Beaver, Katie Williams, Jordan N. Skinner, Casey B. Cempre, Qingxiang Sun, Sharon Shacham, Benjamin R. Stromberg, Matthew K. Summers, Lynne V. Abruzzo, Laura Rassenti, Thomas J. Kipps, Sameer Parikh, Neil E. Kay, Kerry A. Rogers, Jennifer A. Woyach, Vincenzo Coppola, Yuh Min Chook, Christopher Oakes, John C. Byrd, Rosa Lapalombella
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-21 (2021)
Abstract Background Exportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somatic XPO1 point mutations which we foun
Externí odkaz:
https://doaj.org/article/5d10b5b0f27b4de5a2529f4fedcb0538
Autor:
Sara Elgamal, Emanuele Cocucci, Ellen J. Sass, Xiaokui M. Mo, Angela R. Blissett, Edward P. Calomeni, Kerry A. Rogers, Jennifer A. Woyach, Seema A. Bhat, Natarajan Muthusamy, Amy J. Johnson, Karilyn T. Larkin, John C. Byrd
Publikováno v:
JCI Insight, Vol 6, Iss 15 (2021)
In chronic lymphocytic leukemia (CLL) and very likely all cancer types, extracellular vesicles (EVs) are a common mechanism by which intercellular messages are communicated between normal, diseased, and transformed cells. Studies of EVs in CLL and ot
Externí odkaz:
https://doaj.org/article/830710c6a2f04339a049c9c1b33e7304
Autor:
Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps
Publikováno v:
Haematologica, Vol 106, Iss 9 (2021)
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhib
Externí odkaz:
https://doaj.org/article/1f8e5a0d250d49f8bc29eb2cbf686fb6
Autor:
Seema A. Bhat, John Gambril, Leylah Azali, Sunnia T. Chen, Lindsay Rosen, Marilly Palettas, Tracy E. Wiczer, Sujay Kalathoor, Qiuhong Zhao, Kerry A. Rogers, Adam Kittai, Michael Grever, Farrukh Awan, Patrick Ruz, John C. Byrd, Jennifer Woyach, Daniel Addison
Publikováno v:
Blood. 140:2142-2145
Acalabrutinib, a next-generation Bruton’s tyrosine kinase inhibitor (BTKi), associates with dramatic efficacy against B-cell malignancies. Recently, unexplained ventricular arrhythmias (VAs) with next-generation BTKi-therapy have been reported. Yet
Autor:
Max Yano, Chia Sharpe, J. Rachel Lance, Janani Ravikrishnan, Kevan Zapolnik, Xiaokui Mo, Jennifer A. Woyach, Deepa Sampath, Adam S. Kittai, Sumithira Vasu, Seema Bhat, Kerry A. Rogers, Dean A. Lee, Natarajan Muthusamy, John C. Byrd
Publikováno v:
Blood Advances. 6:5641-5654
Successes with anti-CD20 antibodies in chronic lymphocytic leukemia (CLL) and enhanced activity of Fc-engineered vs unmodified antibody therapy suggest a potentially impactful role for natural killer (NK) cells and other innate immune cells in contro
Autor:
Max Yano, Jessica Nunes, Xiaokui Mo, Kerry A. Rogers, Jennifer A. Woyach, John C. Byrd, Natarajan Muthusamy
Publikováno v:
Blood Advances. 6:5440-5448
Cytotoxic T lymphocyte antigen 4 (CTLA4) is a major immune checkpoint and target for cancer immunotherapy. Although originally discovered and primarily studied on T cells, its role on other cell types has also been recognized in recent years. Here we
Autor:
Pooja S. Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J. Pollauf, Amy Zheng, Marilly Palettas, Leylah Azali, Seema A. Bhat, John C. Byrd, Michael R. Grever, Kerry A. Rogers, Jennifer A. Woyach, Adam S. Kittai
Publikováno v:
Leukemia.